Impact Factor 5.890 | CiteScore 2.8
More on impact ›
The growing understanding of the molecular mechanisms of both genetic and acquired diseases offers specific molecular targets for therapeutic intervention. The transfer of genetic material to the tissue-resident cells (gene therapy) or of healthy cells to the diseased tissue (cell therapy), as well as their combination by genetically engineered progenitors, are complementary approaches to correct the specific molecular cause of disease and restore lost function.
The "Preclinical Cell and Gene Therapy" section of Frontiers in Bioengineering and Biotechnology welcomes submissions on both basic and translational aspects of the development of innovative genetic and cellular therapies.
Areas of interest include, but are not limited to:
Indexed in: PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE), Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Semantic Scholar, Ulrich's Periodicals Directory, CLOCKSS, EI Compendex, OpenAIRE, Zetoc
Preclinical Cell and Gene Therapy welcomes submissions of the following article types: Brief Research Report, Case Report, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Preclinical Cell and Gene Therapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact Bioengineering@frontiersin.org